Annual Report 2015
Engineering the Medicines
Nearly one million people
diagnosed with blood
cancer in 2015.
our research: fighting blood cancer
blood cancer cells in
a targeted manner.
our antibody mor208: mode of action
in the treatment
of blood cancer benefiting
the mor208 antibody in clinical development
Which cells are targeted by MOR208?
MOR208 binds to the CD19CD19: Therapeutic target for the treatment of B cell lymphomas and leukemias target molecule that is strongly expressed in the majority of B cell derived tumors. CD19 is expressed more broadly and earlier in the development of B cells than CD20CD20: Therapeutic target for the treatment of B cell lymphomas and leukemias – the target molecule of the marketed cancer drug rituximab. This feature suggests an even broader range of therapeutic applications for MOR208 compared to CD20 antibodies. Therefore, it is considered a particularly promising target molecule for the treatment of lymphomas and leukemias.
In the seven largest markets worldwide, there are more than 150,000 patients afflicted every year with malignant diseases of B cells such as non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (CLLCLL: Chronic lymphocytic leukemia; most common type of cancer of the blood and bone marrow, affecting the B cells).
MOR208 has been engineered to trigger a significantly enhanced immune response using antibody-dependent cell-mediated cytotoxicity (ADCCADCC: Antibody-dependent cell-mediated cytotoxicity; a mechanism of cell-mediated immunity whereby an effector cell of the immune system actively destroys a target cell that has been bound by specific antibodies). This improves a key mechanism for killing tumor cells and offers the potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer. This is why MOR208 will be evaluated in clinical trials in a number of hematological indications as a possible new treatment option for seriously ill cancer patients.
The MOR208 antibody has been engineered to trigger a significantly enhanced immune response using antibody-dependent cell-mediated cytotoxicity (ADCC), which improves the key mechanism for killing tumor cells and offers the potential for enhanced efficacy for the treatment of cancer in comparison to traditional antibodies.